Free Trial

Justin Walsh Analyst Performance

Analyst at B. Riley

Justin Walsh is a stock analyst at B. Riley in the medical sector, covering 7 publicly traded companies. Over the past year, Justin Walsh has issued 9 stock ratings, including strong buy, buy, and hold recommendations. While full access to Justin Walsh's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Justin Walsh's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
9 Last 0 Years
Buy Recommendations
66.67% 6 Buy Ratings
Companies Covered
7 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy11.1%1 ratings
Buy55.6%5 ratings
Hold33.3%3 ratings
Sell0.0%0 ratings

Out of 9 total stock ratings issued by Justin Walsh at B. Riley, the majority (55.6%) have been Buy recommendations, followed by 33.3% Hold and 11.1% Strong Buy.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
85.7% of companies on NASDAQ
6 companies
NYSE
14.3% of companies on NYSE
1 company

Justin Walsh, an analyst at B. Riley, currently covers 7 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
7 companies
100.0%

Justin Walsh of B. Riley specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
4 companies
57.1%
MED PRODUCTS
1 company
14.3%
DIAGNOSTIC SUBSTANCES
1 company
14.3%
MED - DRUGS
1 company
14.3%

Justin Walsh's Ratings History at B. Riley

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
9/18/2025Initiated Coverage$44.03$83.00Buy
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
9/16/2025Lower Price Target$51.49$84.00Buy
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
8/5/2025Downgrade$8.52Hold
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
6/23/2025Lower Price Target$80.26$109.00Buy
VolitionRx Limited stock logo
VNRX
VolitionRx
6/10/2025Upgrade$0.56$3.00Strong-Buy
Clene Inc. stock logo
CLNN
Clene
4/23/2025Initiated Coverage$2.98$30.00Buy
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
4/2/2025Reiterated Rating$33.43Hold
BioLineRx Ltd. stock logo
BLRX
BioLineRx
4/2/2025Reiterated Rating$2.92Hold
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
3/21/2025Lower Price Target$98.85$122.00Buy